Legal status in the United States
Is Setmelanotide legal?
Read at FDA, DEA and WADAPublished by PepVault
Setmelanotide is FDA-approved (Imcivree, first in 2020), is not a federally controlled substance, and is not named on WADA’s Prohibited List, as of November 18, 2026.
Setmelanotide at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Approved (Imcivree, 2020) |
| Compounding | Component of an approved drug (503A condition) |
| DEA schedule | Not controlled |
| Sport (WADA) | Not named on the list |
FDA approval
Setmelanotide is FDA-approved as Imcivree, since 2020, for weight in a few rare genetic and brain-related kinds of obesity.
Imcivree (injection)
Approved for reducing excess weight and keeping it off in rare kinds of obesity: acquired hypothalamic obesity (age 4 and older), and Bardet-Biedl syndrome or a confirmed POMC, PCSK1 or LEPR gene deficiency (age 2 and older). NDA 213793, first approved November 25, 2020.
- Drugs@FDA: Imcivree, application 213793, U.S. Food and Drug Administration. Read .
- Imcivree prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
- Drugs@FDA: Imcivree, application 213793, U.S. Food and Drug Administration. Read .

Compounding
Setmelanotide is the active ingredient of an FDA-approved drug (Imcivree). FDA’s page on bulk drug substances gives three conditions under section 503A for a substance a pharmacy compounds from, and one of them is being a component of an FDA-approved drug product; the 503A and 503B bulks lists don’t name setmelanotide.
The source: “Are components of FDA-approved drug products if an applicable USP or NF monograph does not exist”
- Bulk Drug Substances Used in Compounding (content current as of March 26, 2026), U.S. Food and Drug Administration. Read .
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026), U.S. Food and Drug Administration. Read .
- 503B Bulk Drug Substances List (content current as of May 16, 2024), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
The 2026 Prohibited List doesn’t name setmelanotide, and S0, the class for unapproved substances, doesn’t reach an approved drug.
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about Setmelanotide in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is Setmelanotide FDA approved?
Setmelanotide is FDA-approved as Imcivree, since 2020, for weight in a few rare genetic and brain-related kinds of obesity.
Is Setmelanotide a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is Setmelanotide banned in sport?
The 2026 Prohibited List doesn’t name setmelanotide, and S0, the class for unapproved substances, doesn’t reach an approved drug.
What does FDA say about compounding Setmelanotide?
Setmelanotide is the active ingredient of an FDA-approved drug (Imcivree). FDA’s page on bulk drug substances gives three conditions under section 503A for a substance a pharmacy compounds from, and one of them is being a component of an FDA-approved drug product; the 503A and 503B bulks lists don’t name setmelanotide.